FDA expands Anktiva approval for BCG-unresponsive non-muscle-invasive bladder cancer to cover papillary and CIS disease
IBRX•The FDA expanded Anktiva’s approval for BCG-unresponsive non-muscle-invasive bladder cancer to cover both papillary and CIS disease.
1. Expanded approval
The FDA expanded Anktiva’s approval for BCG-unresponsive non-muscle-invasive bladder cancer to cover both papillary and CIS disease.
